Synthekine Funding & Investors
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
synthekine.comTotal Amount Raised: $289,500,000
Synthekine Funding Rounds
Series C
$100,000,000
Series C Investors
Column GroupSeries B
$107,500,000
Series B Investors
Deerfield ManagementHenderson Global InvestorsEmerson CollectiveTCG Crossover ManagementSamsara BioCapitalCanaan PartnersOmega FundsLilly Asia VenturesColumn GroupRock Springs CapitalRa Capital ManagementSeries A
$82,000,000
Series A Investors
Canaan PartnersSamsara BioCapitalColumn Group
Funding info provided by Diffbot.